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Evaluation of Neonatal Hyperbilirubinemia?Neonatal hyperbilirubinemia remains a public health
concern as documented by recent reports of kernicterus in
otherwise healthy term and near-term newborns. Fetal-
maternal blood group incompatibility, a previously affected
sibling, glucose-6-phosphate dehydrogenase deficiency,
cephalohematomas/bruising, and nonoptimal sucking/
nursing are major risk factors for hyperbilirubinemia in
term newborns.1 Clinical data and morphologic features of
erythrocytes have been used to predict and diagnose
neonatal hyperbilirubinemia.2,3 However, no single test can
determine the cause of neonatal hyperbilirubinemia.
The direct antiglobulin test (DAT), also known as direct
Coombs test, is a screening technique used to detect
nonagglutinating antibodies on human red blood cells
(RBCs). When a pregnant woman’s serum includes a clini-
cally significant immunoglobulin G (IgG) antibody directed
against an antigen on the RBCs of her fetus, placental
transfer of the antibody into the fetal circulation may
result in the destruction of fetal RBCs, leading to hemolytic
disease of the newborn (HDN). DAT is considered to be an
important test to identify neonates who are at risk of HDN.
Positive or negative DAT results have been discussed in
many studies conducted during the neonatal period. A
positive DAT is a strong predictor of hyperbilirubinemia in
ABO-incompatibility, Rhesus (Rh) disease, and antibodies
against other blood groups in newborns. Nevertheless,
there is a debate over the role of DAT screening in pre-
dicting HDN.
In this issue of Pediatrics and Neonatology, Valsami
et al4 retrospectively reviewed routine DAT results in cord
blood and correlated the results with blood type, devel-
opment of hyperbilirubinemia, and the need for photo-
therapy. They found 70 positive DAT cases in 2695 cord
blood samples. Sixty-seven cases of DAT positivity were
attributed to ABO incompatibility, three cases were
attributed to maternal alloimmunization (anti-Fya and anti-
JKb), and one case to maternal IgG autoantibodies that
developed after methyldopa treatment. The strength of
DAT positivity tends to correlate with the need for andhttp://dx.doi.org/10.1016/j.pedneo.2015.03.002
1875-9572/Copyright ª 2015, Taiwan Pediatric Association. Published bduration of phototherapy. The results were consistent with
previous studies that positive DAT is associated with a
fourfold increased risk of neonatal hyperbilirubinemia and
that the grades of positivity are associated with the dura-
tion of phototherapy.5
Among the limitations of this study that have been
acknowledged by the authors are the predictive value and
cost-benefit information of routine DAT. A positive DAT has
only 23% predictive value for ABO HDN.6 A negative DAT
does not rule out ABO HDN or exclude a nonimmune he-
molytic etiology underlying clinically significant hyper-
bilirubinemia. Some institutions consider routine DAT is a
cost-ineffective strategy and it is not supported by clin-
ical guidelines.7 Although some clinical practice guidelines
recommend that if the maternal blood is group O, Rh-
positive, it is an option to test the cord blood for the in-
fant’s blood type and DAT, however, it is not required if
there is adequate surveillance, risk assessment prior to
discharge, and appropriate follow up.7 Many technical pit-
falls including Wharton jelly in cord blood specimens,
spontaneous RBC agglutination, and poor washing tech-
niques can result in a false-positive DAT. In this issue of
Pediatrics and Neonatology, Valsami et al4 directly punc-
tured the umbilical vein and implemented a fully auto-
mated method to avoid Wharton jelly contamination and to
overcome technical pitfalls, respectively.
The investigation of neonatal hyperbilirubinemia should
be individualized, and infants with early-onset or severe
hyperbilirubinemia need more aggressive study. The com-
bined results of DAT and its strength of reaction may be
useful in early detection of infants with the risk of severe
jaundice. Further research is needed to determine the
sensitivity and specificity of the DAT and its role in newborn
infants with particular hematologic abnormalities.Conflicts of interest
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